We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NVNI:NASDAQNvni Group Limited Analysis

Data as of 2026-05-25 - not real-time

$1.20

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Nvni Group Limited trades at $1.20, which sits just below its 20‑day SMA of $1.214 and 50‑day SMA of $1.241, indicating short‑term weakness, while the 200‑day SMA remains far higher at $3.28, underscoring a long‑term bearish trend. Technical indicators such as a bearish MACD (‑0.048 vs. signal ‑0.045) and a neutral RSI of 49 reinforce the downside bias, and the stock is hovering near its identified support at $0.96 with resistance around $1.43. Volume is increasing, but the 30‑day volatility of 77% and a beta of 2.2 reveal an extremely volatile, high‑beta profile that amplifies price swings. Fundamentally, the company posted a revenue decline of 2.5% to $196.7 M, a gross margin of 65% but an operating margin of only 4.8%, and a net loss margin of –57%, resulting in negative EPS (‑$2.39 trailing, ‑$0.20 forward). Cash balances of $13.5 M are dwarfed by $63.6 M of debt, and free cash flow is deeply negative at –$31.8 M, indicating liquidity strain. Despite these challenges, the price‑to‑sales ratio of 0.07 and a DCF‑derived fair value of $1.98 suggest the market may be discounting the stock by over 40%, with an implied upside of more than 560% to the consensus $8 target. However, the absence of dividends and a negative book value per share (‑$2.77) signal limited financial cushion.
Given the confluence of bearish technical signals, deteriorating earnings, high leverage, and extreme volatility, the stock presents a high‑risk profile, but its ultra‑low valuation multiples and substantial upside potential keep it on the radar for speculative investors seeking a turnaround play.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 8/10

Key Factors

  • Price below 20‑day and 50‑day SMAs
  • Bearish MACD and high volatility
  • Negative earnings and widening losses

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • DCF fair value above current price
  • Low price‑to‑sales multiple
  • Continued cash flow deficit and high debt

Long Term

> 3 years
Positive
Model confidence: 4/10

Key Factors

  • Potential upside to $8 consensus target
  • Strong gross margin indicating operational leverage
  • Opportunity for market expansion in Brazil/Latin America

Key Metrics & Analysis

Financial Health

Revenue Growth-2.50%
Profit Margin-57.40%
P/E Ratio-6.0
ROA-4.51%
P/B Ratio-0.4
Op. Cash Flow$8.0M
Free Cash Flow$-31800750
Industry P/E39.5

Technical Analysis

TrendBearish
RSI49.2
Support$0.96
Resistance$1.43
MA 20$1.21
MA 50$1.24
MA 200$3.28
MACDBearish
VolumeIncreasing
Fear & Greed Index91.8

Valuation

Fair Value$1.98
Target Price$8.00
Upside/Downside566.67%
GradeUndervalued
TypeValue

Risk Assessment

Beta2.20
Volatility77.44%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskHigh
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.